Global Artificial Pancreas Devices Systems Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Artificial Pancreas Devices Systems Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetesa continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
Artificial Pancreas Devices Systems report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Artificial Pancreas Devices Systems market is projected to reach US$ 199.8 million in 2034, increasing from US$ 89 million in 2022, with the CAGR of 12.1% during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
Medtronic monopolizes the global Artificial Pancreas Devices Systems market, holding a share about 100%.
North America is the largest market, with a share about 60%, followed by Europe, have a share about 30 percent.
In terms of product, Threshold Suspended Device Systems is the largest segment, with a share over 60%. And in terms of application, the largest application is Hospitals
, followed by Clinics.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Artificial Pancreas Devices Systems market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Medtronic
Bigfoot Biomedical
Beta Bionics
Admetsys
Insulet
Tandem Diabetes Care
Defymed
Segment by Type
Threshold Suspended Device Systems
Hybrid Closed-loop APDS
Other Systems
Hospitals
Clinics
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Artificial Pancreas Devices Systems market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Artificial Pancreas Devices Systems, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Artificial Pancreas Devices Systems industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Artificial Pancreas Devices Systems in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Artificial Pancreas Devices Systems introduction, etc. Artificial Pancreas Devices Systems Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Artificial Pancreas Devices Systems market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetesa continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
Artificial Pancreas Devices Systems report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Artificial Pancreas Devices Systems market is projected to reach US$ 199.8 million in 2034, increasing from US$ 89 million in 2022, with the CAGR of 12.1% during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
Medtronic monopolizes the global Artificial Pancreas Devices Systems market, holding a share about 100%.
North America is the largest market, with a share about 60%, followed by Europe, have a share about 30 percent.
In terms of product, Threshold Suspended Device Systems is the largest segment, with a share over 60%. And in terms of application, the largest application is Hospitals
, followed by Clinics.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Artificial Pancreas Devices Systems market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Medtronic
Bigfoot Biomedical
Beta Bionics
Admetsys
Insulet
Tandem Diabetes Care
Defymed
Segment by Type
Threshold Suspended Device Systems
Hybrid Closed-loop APDS
Other Systems
Segment by Application
Hospitals
Clinics
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Artificial Pancreas Devices Systems market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Artificial Pancreas Devices Systems, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Artificial Pancreas Devices Systems industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Artificial Pancreas Devices Systems in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Artificial Pancreas Devices Systems introduction, etc. Artificial Pancreas Devices Systems Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Artificial Pancreas Devices Systems market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices